Pacira Pharmaceuticals (PCRX) PT Lowered to $52 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq futures outperform after Nvidia puts AI fears to rest
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of easing Middle East supply disruptions
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Pacira Pharmaceuticals (PCRX) PT Raised to $39 at BMO Capital on 3Q Report; 'Higher Gross Margin and Lower R&D'
November 9, 2017 9:56 AM ESTBMO Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $39.00 (from $38.00) while maintaining a Market Perform rating, following the company's third quarter earnings report.
Analyst Gary Nachman notes a positive outlook on the shares, as the company reported earnings per share... More
UPDATE: H.C. Wainwright Assumes Pacira Pharmaceuticals (PCRX) at Buy
November 9, 2017 7:17 AM EST(Updated - November 9, 2017 7:35 AM EST)
(updated to add analyst comment)
H.C. Wainwright assumes coverage on Pacira Pharmaceuticals (NASDAQ: PCRX) with a Buy rating and a price target of $52.00.
Analyst Oren Livnat comments "Slow and steady wins... More
Pacira Pharma (PCRX) Tops Q3 EPS by 17c, Miss on Revenues
November 8, 2017 7:37 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.11, $0.17 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $67.3 million versus the consensus estimate of $70.04 million.
... More
